Newly developed prediction models can identify infants with bronchopulmonary dysplasia (BPD) — a chronic lung condition that primarily affects premature newborns who need oxygen therapy — who are at the highest risk of developing pulmonary hypertension (PH), according to a large, multicenter study. After analyzing data from more than…
News
Higher blood levels of immunoglobulin E (IgE), an immune molecule typically linked to allergies, are associated with worse right heart function in people with pulmonary arterial hypertension (PAH), according to a study. While the left side of the heart pumps oxygen-rich blood to the body, the right side pumps…
People with pulmonary arterial hypertension (PAH) often have abnormalities in the coronary microvasculature, or the tiny blood vessels that are needed to deliver oxygen and nutrients to muscle cells in the heart, a small study shows. Importantly, problems with these blood vessels may contribute to heart disease and…
Scientists have developed an artificial intelligence-powered model that may help identify premature infants at risk for pulmonary hypertension (PH) and bronchopulmonary dysplasia (BPD) using noninvasive eye pictures taken during standard screenings. “Our findings suggest that information about a baby’s lung and heart health may already be present in these…
Following positive results from a Phase 3 clinical study, United Therapeutics plans to submit an application to the U.S. Food and Drug Administration (FDA) by the second half of 2026 seeking approval for its experimental oral therapy ralinepag as a treatment for pulmonary arterial hypertension (PAH). United announced…
GSK (formerly called GlaxoSmithKline) has acquired rights to HS235, an experimental treatment for pulmonary hypertension (PH), now in early clinical testing, that the buyer hopes will become a new standard of care for PH. The therapy’s developer 35Pharma announced that it’s being acquired by GSK for $950…
Global advocacy group Phaware has launched a new app, called Heart Works – phaware, to provide a centralized hub for education, health tracking, and community connection for those living with pulmonary hypertension (PH). The app is designed to…
People with pulmonary arterial hypertension (PAH) who were treated with the inhaled therapy seralutinib in a clinical trial tended to have better improvements in exercise capacity than those given a placebo, data show. However, the difference between the groups failed to meet a prespecified threshold for statistical significance. That…
In pulmonary arterial hypertension (PAH), blood vessel cells in the lungs release exosomes, or cellular shipping containers, filled with a signaling molecule called microRNA-21 (miR-21) that are taken up by heart cells to help limit heart damage, a new study shows. “These findings identify exosomal miR-21 as a key…
Treatment with molecular shipping containers called extracellular vesicles, loaded with a signaling molecule called cAMP, reduced the severity of pulmonary hypertension (PH) in a rat model of the disease, a new study reports. The data indicated that these packages of signaling molecules, which they dubbed cAMP-EVs, reduced the abnormal…
The one-minute sit-to-stand test (STST), which measures the number of times a patient can sit down and stand up from a chair in 1 min, may predict adverse outcomes in adults with pulmonary hypertension (PH), according to a study. In particular, worse performance in the STST (14 repetitions or…
Mutations in the gene SOX17 are linked to a severe form of pulmonary arterial hypertension (PAH) that most often manifests in childhood, though these mutations are also found in some adults with adult-onset PAH, according to a new study. Findings suggest that the specific type and location of mutations in…
